Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study

NCT03056209 is registered in ClinicalTrials.gov with Yungjin Pharm. Co., Ltd. as lead sponsor.

NCT NCT03056209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03056209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study
Lead sponsor
Yungjin Pharm. Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 26, 2017
Completion date
April 16, 2018
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melas syndrome, mitochondrial respiratory chain deficiencies